| [1] |
Lincz LF, Seorgie FE, Garg MB, et al Identification of a novel sjngle nueleotide polymorphism in the first tandem repeat quenee of the thymidylate synthase 2R allele[J] Int J Cancer, 20 07, 120(9):1930-4.
|
| [2] |
Chen J, Hunter DJ, Stampfer MJ, et al Polymorphism in the thymidylate synthase promoter enhsncer region modifies the risk and survival of colorectal cancer[J] Cancer Epidemiol Biomarkers Prev,2003,12(10):958-62.
|
| [3] |
Adleff V, Hitre E, Köves I,et al Helerozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients[J].Int J Cancer, 2004, 108(6):852-6.
|
| [4] |
Graziano F,Kawakami K,Watanabe G,et al Association of thymidylate synthase polymorphisms with gastric cancer susceptibility[J].Int J Cancer, 2004, 112(6):1010-4.
|
| [5] |
Mandola MV,Stoehlmacher J,Zhang W, et al.A 6bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels[J] Pharmacogenetics, 2004, 14(5):319-27.
|
| [6] |
Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy[J]. J Clin Oncol,2007, 25(10):1247-54.
|
| [7] |
Lamas MJ, Duran G, Gomez A,et al. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response tochemoradiotherapy in rectal cancer patients[J]. Int J Radiat Oncol Biol Phys,2012,82(1):138-44.
|
| [8] |
Lamas MJ, Duran G, Balboa E, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouraciloxaliplatin regimen in patients with metastatic colorectal cancer [J] Pharmacogenomics, 2011, 12(3):433-42.
|
| [9] |
He WX, Li DM, Zhou WH, et al. Relationship between ERCC1 gene polymorphism and oxaliplatin-based chemotherapeutic effect in colorectal cancer[J]. Guangdong Yi Xue,2012,33(10):1408-10. [ , ÷, ΰ , . ERCC1 ̬ ֱ ɳ Ϊ Ч Ĺ ϵ[ J ] . 㶫ҽ ѧ,2012,33(10):1408-10. ]
|
| [10] |
Danenberg PV, Malli H, Swenson S. Thymidylate synthase inhibitors[J]. Semin Oncol,1999,26(6):621-31.
|
| [11] |
Ishida Y, Kawakami K, Tanaka Y, et al. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer [J].Anticancer Res,2002,22(5):2805-9.
|
| [12] |
Morganti M, Ciantelli M, Giglioni B, et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers[J]. Eur J Cancer,2005 41 (14):2176-83.
|
| [13] |
Yawata A, Kim SR, Miyajima A, et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents[J]. Cancer Chemother Pharmacol, 2005, 56(5):465-72.
|
| [14] |
Brody JR, Hucl T, Gallmeier E,et al. Genomic copy number changes affecting the thymidylate synthase (tyms) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy[J]. Cancer Res, 2006, 66(19):9369-73.
|
| [15] |
Watson RG, Muhale F, Thorne LB, et al. Ampli?cation of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy[J]. Eur J Cancer, 2010, 46(18):3358-64.
|
| [16] |
Huang ZH, Hua D, Li LH. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with Xuorouracil-based adjuvant chemotherapy in Chinese population[J]. Cancer Chemother Pharmacol,2009,63(5):911-8.
|
| [17] |
Cui YH, Liu TS, Zhuang RY, et al. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer[J]. J Dig Dis,2009,10(2):118-23.
|
| [18] |
Vi l l a f r a n c a E , O k r u z h n o v Y, D o m i n g u e z M A , e t al . Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer [J]. J Clin Oncol, 2001, 19 (6):1779-86.
|
| [19] |
Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5- FU chemotherapy[J]. Pharmacogenomics J, 2001,1(1): 65-70.
|
| [20] |
Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer[J]. Int J Oncol, 2001, 19(2):383-6.
|
| [21] |
Park DJ, Stoehlmacher J, Zhang W,et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer[J]. Int J Colorectal Dis,2002, 17(1):46-9.
|
| [22] |
Matasui T, OmuraK, Kawakami K,et al. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer[J]. Oncol Rep,2006,16(5):1111-5
|
| [23] |
Kakimoto M, Uetake H, Osanai T, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test[J]. Cancer Lett,2005,223(1): 103-11.
|
| [24] |
Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene[J]. Cancer Epidemiol Biomarkers Prev, 2000, 9(12): 1381-5.
|
| [25] |
Mandola MV, Stoehlmacher J, Muller-Weeks S,et al. A novel single nucleotide polymorphism within the 5’tandem repeat polymorphism of the thymidylate synthase gene abolishes USF1 binding and alters transcriptional activity[J]. Cancer Ras, 2003, 63 (11) : 2898-904.
|
| [26] |
Ulrich CM, Bigler J, Bostick R, et al. Thymidylate synthase promoter polymorphism interaction with folate intake and risk of colorectal adenomas[J]. Cancer Ras, 2002, 62(12): 3361-4.
|
| [27] |
Won DY, Kim SH, Hur H, et al. Chemotherapeutic responsibility according to polymorphism of ercc1, xrcc1 and gstp1 in gastric cancer patients receiving oxaliplatin based chemotherapy[J]. J Korean Surg Soc, 2010, 78(6): 350-6.
|
| [28] |
Liu YP, Ling Y, Zhang YP, et al. Predictive values of platinumrelated gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy[J]. Zhonghua Yi Xue Za Zhi,2011,91(4):256-9.[ Ƽ, , Ƽ, . ҩ ػ ̬ ԶԺ ɳ θ Ч Ӱ [J] л ҽѧ ־, 2011, 91(4):256-9.]
|
| [29] |
Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis[J]. Clin cancer Res,2011,17(6):1632-40.
|
| [30] |
Ruzzo A, Graziano F, Kawakami K,et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy[J].J Clin Oncol,2006, 24 (12):1883-91.
|
| [31] |
Ruzzo A, Graziano F, Loupakis F,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy[J]. J Clin Oncol,2007,25(10):1247-54.
|
| [32] |
Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer[J]. Clin Cancer Res,2005, 11 (17):6212-7.
|
下载:
